Comparing Gemifloxacin and Cefpodoxime for Chronic Bronchitis
Author Information
Author(s): Chatterjee S., Biswas T., Dutta A., Sengupta G., Mitra A., Kundu S.
Primary Institution: Institute of Postgraduate Medical Education and Research, Kolkata, India
Hypothesis
Is gemifloxacin as effective and safe as cefpodoxime for treating acute exacerbation of chronic bronchitis?
Conclusion
Gemifloxacin is comparable to cefpodoxime in effectiveness and safety for treating acute exacerbation of chronic bronchitis.
Supporting Evidence
- 84.6% of patients on gemifloxacin showed treatment success compared to 83.3% on cefpodoxime.
- Adverse events were mild and self-limiting in both groups.
- Both treatments had good tolerability and patient compliance.
Takeaway
This study looked at two medicines to help people with a cough and breathing problems. Both worked about the same, and neither caused serious side effects.
Methodology
A randomized, controlled, single-blind trial comparing gemifloxacin and cefpodoxime in patients with acute exacerbation of chronic bronchitis.
Potential Biases
The investigator assessing subjects was unaware of treatment allocation, but the study design was not fully blinded.
Limitations
The study could not be double-blind due to financial constraints, and microbial efficacy was not assessed.
Participant Demographics
Adult patients aged 25 to 70 years, with a mean age of approximately 59 years, predominantly male.
Statistical Information
P-Value
0.04
Confidence Interval
–19.43 to 22.6%
Statistical Significance
p=0.90
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website